טוען...
Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials
To save valuable time and resources in new drug development, Phase I/II clinical trials with toxicity control and drug efficacy as dual primary endpoints have become increasingly popular. Escalation with over-dose control (the EWOC) is a Bayesian adaptive Phase I clinical trial design that can accur...
שמור ב:
| הוצא לאור ב: | Contemp Clin Trials |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4871606/ https://ncbi.nlm.nih.gov/pubmed/26012358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2015.05.014 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|